Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
Investing.com - Citizens JMP initiated coverage on Hinge Health Inc (NYSE:HNGE) with a Market Outperform rating and a price target of $58.00.
The coverage initiation follows Hinge Health’s initial public offering on May 22, when the company’s shares were priced at $32.00.
Citizens JMP stated that Hinge Health is working to build a new health system with reduced costs for employers while improving experiences and outcomes for patients.
The firm noted that Hinge Health utilizes technology to scale and automate the delivery of care, beginning with physical therapy services.
The $58.00 price target represents a significant premium over the company’s IPO price, reflecting Citizens JMP’s positive outlook on the digital healthcare provider’s business model.
In other recent news, Hinge Health has been the subject of several analyst reviews and company developments. Truist Securities reiterated its buy rating on Hinge Health, maintaining a $48.00 price target after a meeting with company executives. The firm noted strong business momentum and highlighted the promising start of Hinge Health’s 2026 selling season. Additionally, Hinge Health announced the launch of HingeSelect, a provider network for musculoskeletal care, with Truist maintaining its positive outlook on the company’s future. Raymond (NSE:RYMD) James initiated coverage with an outperform rating and a $45.00 price target, citing Hinge Health’s durable growth profile and strong partner network. Needham also initiated coverage with a buy rating and a $47.00 price target, emphasizing the company’s leadership in the virtual musculoskeletal care market. Evercore ISI joined with an outperform rating and a $50.00 price target, noting Hinge Health’s attractive business model and growth prospects. These developments reflect a consistent confidence among analysts in Hinge Health’s market position and potential for growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.